BIOMODICS ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  1.8% 3.8% 7.2% 1.8% 2.3%  
Credit score (0-100)  72 51 32 70 63  
Credit rating  A BBB BBB A BBB  
Credit limit (kDKK)  1.6 0.0 0.0 2.6 0.1  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  3,135 1,916 1,253 4,349 2,809  
EBITDA  718 -451 -644 2,059 402  
EBIT  670 -481 -672 1,999 257  
Pre-tax profit (PTP)  671.4 -487.2 -701.4 1,951.8 292.7  
Net earnings  527.8 -460.8 -680.4 1,674.8 392.1  
Pre-tax profit without non-rec. items  671 -487 -701 1,952 293  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  70.6 40.6 146 587 442  
Shareholders equity total  2,099 1,638 958 2,633 3,025  
Interest-bearing liabilities  45.5 563 1,334 99.4 608  
Balance sheet total (assets)  3,897 2,741 2,985 8,064 6,684  

Net Debt  -1,767 -411 679 -3,341 -2,856  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  3,135 1,916 1,253 4,349 2,809  
Gross profit growth  -19.8% -38.9% -34.6% 247.0% -35.4%  
Employees  4 0 3 0 0  
Employee growth %  0.0% -100.0% 0.0% -100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,897 2,741 2,985 8,064 6,684  
Balance sheet change%  -20.5% -29.7% 8.9% 170.1% -17.1%  
Added value  718.5 -451.4 -643.8 2,027.3 401.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -97 -44 77 381 -290  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 -1.0 -2.0 1.0 2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  21.4% -25.1% -53.6% 46.0% 9.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  15.4% -14.2% -23.1% 36.7% 4.2%  
ROI %  31.6% -21.4% -28.4% 78.9% 9.7%  
ROE %  25.3% -24.7% -52.4% 93.3% 13.9%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  71.8% 59.8% 32.1% 69.9% 57.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -246.0% 91.0% -105.4% -162.2% -710.9%  
Gearing %  2.2% 34.4% 139.3% 3.8% 20.1%  
Net interest  0 0 0 0 0  
Financing costs %  12.6% 5.1% 4.1% 10.7% 4.4%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  4.6 2.5 1.4 6.6 2.8  
Current Ratio  2.1 2.5 1.4 1.4 1.7  
Cash and cash equivalent  1,812.7 973.8 655.6 3,440.0 3,463.7  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,976.7 1,597.6 843.4 1,987.3 2,508.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  180 0 -215 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  180 0 -215 0 0  
EBIT / employee  168 0 -224 0 0  
Net earnings / employee  132 0 -227 0 0